This paper is only available as a PDF. To read, Please Download here.
Background
IDO1 inhibition with a 1st-generation inhibitor has shown promising clinical benefit
in melanoma patients, as well as exacerbated toxicity, when combined with ipilimumab.
We have identified a novel class of IDO1 inhibitors (IDO1i), which surpass the potency,
selectivity and pharmacokinetic parameters of 1st-generation IDO1i.
Methods
IDO1 inhibition was assessed from kynurenine (kyn) levels produced by stimulated HeLa
or dendritic cell cultures or recombinant IDO1. T-cell proliferation was measured
using eFluor®670 dye. CT26 tumours were grown SC in Balb/c mice. IDO1i and kyn levels
were measured by LC/MS/MS. Assessment of immune parameters was performed on tumour-infiltrating
leucocytes by FACS.
Findings
These IDO1i potently inhibit cellular IDO1 with IC50 ≤ 10 nM, retain their potency in human serum (IC50 ≤ 10 nM) and restore T-cell proliferation, which is inhibited by allogeneic IDO1 + DC (EC50 = 2–5 nM). They exhibit PK characteristics consistent with once-daily dosing in humans.
One of these molecules, selected for clinical evaluation, has undergone extensive
characterisation, including the relationship between plasma levels of compound and
kyn, and its impact on tumour growth and immune parameters in mouse syngeneic tumours,
as single agent and in combination with various immune checkpoint inhibitors.
Discussion
This study provides the preclinical basis for clinical evaluation of a 2nd-generation
IDO1i in combination with other immunotherapies.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
